Translate the text from English to Welsh.



 
Since the start of the pandemic, we have worked closely with the other UK nations to identify and deploy novel therapies for the treatment of COVID\-19\.  In determining which treatments should be routinely used in the management of COVID\-19 we are guided by the advice of the Research to access pathway for investigational drugs for COVID\-19 (RAPID C\-19\) initiative and the UK national clinical expert group on COVID therapeutics.  This approach has served us well.


Through our collaborative efforts we are now able to offer people with severe illness treatments including remdesivir, tocilizumab and sarilumab, which in many cases mean they no longer need critical care when they are admitted to hospital. More recently we have been able to provide more than 5000 of the most vulnerable people in Wales early treatment with the antiviral medicines nirmatrelavir/ritonavir, and molnupiravir, and the neutralising antibody sotrovimab, to prevent them being hospitalised at all. In combination with our vaccination programme, enabling people to access evidence\-based treatments is reducing demand on our NHS and ultimately saving lives.


In recent weeks, I have received correspondence from Members of the Senedd regarding the UK Government’s decision not to procure the neutralising monoclonal antibody combination tixagevimab/cilgavimab (Evusheld) for the pre\-exposure prophylaxis of COVID\-19\. 


In particular, I have been asked what plans the Welsh Government has for directly procuring Evusheld outside the pan\-UK procurement arrangements we have established during the pandemic. I can confirm that at this stage we have no intention to procure Evusheld directly – doing so would go against the advice of RAPID C\-19 and the national clinical expert group both of which have advised against procuring Evusheld against at this time. 


We will continue to be guided by the clinical advice on therapeutic options which has been so successful throughout the pandemic. If compelling evidence of its effectiveness becomes available, we will work with other UK governments to secure supplies of Evusheld for those people who might benefit. I am therefore pleased the National Institute for Health and Care Excellence has already started work on its single technology appraisal of Evusheld with an anticipated publication date of early summer next year.


I will provide a further statement on access to Evusheld should the position change.







Translation:


 
Ers dechrau’r pandemig, rydym wedi bod yn gweithio’n agos gyda gwledydd eraill y DU i nodi a chyflwyno therapïau newydd ar gyfer trin COVID\-19\. Wrth benderfynu pa driniaethau y dylid eu defnyddio’n rheolaidd wrth reoli COVID\-19 cawn arweiniad gan gyngor menter ymchwilio i lwybr mynediad ar gyfer cyffuriau ymchwiliol ar gyfer COVID\-19 (RAPID C\-19\) a grŵp arbenigol clinigol cenedlaethol y DU ar therapiwteg COVID. Mae’r dull gweithredu hwn wedi gweithio’n dda i ni.


Drwy ein hymdrechion ar y cyd rydym bellach yn gallu cynnig triniaethau i bobl â salwch difrifol gan gynnwys remdesivir, tocilizumab a sarilumab, sydd mewn llawer o achosion yn golygu nad oes angen gofal critigol arnynt fwyach pan gânt eu derbyn i’r ysbyty. Yn fwy diweddar, rydym wedi gallu rhoi triniaeth gynnar i fwy na 5000 o’r bobl sydd fwyaf agored i niwed yng Nghymru gyda’r meddyginiaethau gwrthfeirol nirmatrelavir/ritonavir, a molnupiravir, a'r gwrthgorff sy’n niwtraleiddio, sotrovimab, er mwyn eu hatal rhag mynd i’r ysbyty o gwbl. Yn ogystal â’n rhaglen frechu, mae galluogi pobl i gael gafael ar driniaethau sy’n seiliedig ar dystiolaeth yn lleihau’r galw ar y GIG ac yn y pen draw yn achub bywydau.


Yn ystod yr wythnosau diweddar, rwyf wedi cael gohebiaeth gan Aelodau o’r Senedd ynghylch penderfyniad Llywodraeth y DU i beidio â chaffael cyfuniad y gwrthgorff monoclonaidd sy’n niwtraleiddio, tixagevimab/cilgavimab (Evusheld), ar gyfer proffylacsis cyn\-gysylltiad COVID\-19\. 


Yn benodol, mae pobl wedi gofyn i mi pa gynlluniau sydd gan Lywodraeth Cymru er mwyn caffael Evusheld yn uniongyrchol y tu allan i drefniadau caffael y DU gyfan a sefydlwyd yn ystod y pandemig. Gallaf gadarnhau, nid ydym yn bwriadu caffael Evusheld yn uniongyrchol ar hyn o bryd – byddai gwneud hynny yn mynd yn groes i gyngor RAPID C\-19 a’r grŵp arbenigol clinigol cenedlaethol, gan fod cyngor presennol y ddau hyn yn argymell yn erbyn caffael Evusheld.


Byddwn yn parhau i gael ein harwain gan y cyngor clinigol ar opsiynau therapiwtig, sydd wedi bod yn llwyddiannus iawn drwy gydol y pandemig. Os bydd tystiolaeth gymhellol o’i effeithiolrwydd yn dod i’r amlwg, byddwn yn gweithio gyda llywodraethau eraill y DU i sicrhau bod cyflenwad o Evusheld ar gael i’r bobl hynny all gael budd ohono. Felly, rwy’n falch bod y Sefydliad Cenedlaethol dros Ragoriaeth mewn Iechyd a Gofal eisoes wedi dechrau gweithio ar ei arfarniad technoleg unigol o Evusheld, a disgwylir iddo gael ei gyhoeddi yn gynnar yn yr haf y flwyddyn nesaf.


Byddaf yn darparu datganiad pellach ar fynediad at Evusheld os bydd y sefyllfa’n newid.